Forward P/S Multiple: CASI Pharmaceuticals, Inc (CASI)

CASI Pharmaceuticals is expanding its drug portfolio by licensing Western developments for the Chinese market. The expected P/S valuation facilitates an objective analysis of revenue, while the 0.10 figure serves as the current metric. The company is valued as a reliable conduit for global therapies; however, geopolitical pressure and delisting risks create significant barriers to business expansion between the US and China.

CASI CASI Pharmaceuticals, Inc.: Market Cap to Expected Sales Ratio in the range 07/04/2022 - 02/28/2026

Comprehensive metric breakdowns and analytics for casipharmaceuticals.com (CASI)

- current price and projected stock value:

Stock Price CASI Pharmaceuticals, Inc.|CASI - Consensus Target

- company stock exchange capitalization indicators:

Market Capitalization CASI Pharmaceuticals, Inc|CASI - Enterprise Value

- issuer book value statistics:

Net Assets per Single Share CASI Pharmaceuticals|CASI - Book Valuation of Business|Market Capitalization to Book Value Ratio casipharmaceuticals.com|CASI - Company Total Asset Base

- issuer credit burden and liquidity indicators:

Total Debt to Equity Ratio CASI Pharmaceuticals|CASI - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity CASI Pharmaceuticals, Inc.|CASI - Company Aggregate Indebtedness|Debts to Book Capitalization CASI Pharmaceuticals, Inc|CASI - Company Long-Term Loans and Borrowings|Company Short-Term Debts CASI Pharmaceuticals|Quick Liquidity casipharmaceuticals.com

- business earnings and investment ratios data:

CASI - Final Profit|Expected Profit CASI Pharmaceuticals|CASI - Price to Earnings Ratio|Forward P/E Multiple CASI Pharmaceuticals, Inc.|CASI - PEG Multiple|EV/EBITDA Multiple CASI Pharmaceuticals, Inc|CASI - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) CASI Pharmaceuticals|CASI - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months casipharmaceuticals.com|CASI - Earnings growth in current year|Expected earnings per share growth for next year CASI Pharmaceuticals

- sales volume and revenue indicators:

CASI - Company Total Sales|Projected Sales Volume CASI Pharmaceuticals, Inc.|CASI - Price-to-Revenue Coefficient|Forward P/S Multiple CASI Pharmaceuticals, Inc

Fundamental valuation:CASI Pharmaceuticals, Inc CASI

Manufactured products of CASI Pharmaceuticals, Inc.

This metric compares the current market value of CASI Pharmaceuticals (CASI) with its projected sales volume, allowing for an assessment of whether the shares are overvalued or trading at a discount relative to future cash flows. By analyzing the expected price-to-sales ratio, an investor can confirm the business's resilience, where patent protection and stable demand for oncology drugs in China minimize the risks of a sharp revenue decline.

Key competitors

Forward P/S Multiple TGTX (TG Therapeutics)|ACLX - Forward Price-to-Revenue Multiple|Disc Medicine Corp - Forward P/S Multiple|SNDX - Forward P/S Multiple|Kura Oncology, Inc. (KURA) - Price-to-Projected Revenue Ratio|ADCT - Market Cap to Expected Sales Ratio|FHTX (Foghorn Therapeutics, Inc.) - Forward P/S Multiple|Vor Biopharma, Inc. (VOR) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple NKTX (Nkarta, Inc.)|COEP (coeptistx.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Actinium Pharmaceuticals ATNM|ESLA (estrellabio.com) - Future Price to Revenue|Marker Bio - Forward P/S Multiple|Forward Price to Sales INAB (IN8bio Inc.)|ERNA: Forward P/S Multiple|GT Biopharma Corporation (GTBP) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Aptose Biosciences Inc|BPTH: Forward Price to Sales|Price-to-Projected Revenue Ratio MEI Pharma (MEIP)|Forward Price-to-Revenue Multiple vincerx.com VINC